OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Want to cut your energy bills? Here’s how five experts are doing it 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NEW YORK, Feb. 27, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Endologix, Inc. (NASDAQ:ELGX) between August 2, 2016 and November 16, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. To get more information go to:
http://www.zlk.com/pslra/endologix-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the requisite clinical data for FDA premarket approval of its Nellix EndoVascular Aneurysm Sealing System; and (2) as a result, Endologix’s public statements were materially false and misleading at all relevant times.
On November 16, 2016, Endologix announced that the FDA requested two-year follow-up data on patients enrolled in the EVAS-FORWARD IDE study to assess Nellix. On this news, shares of Endologix fell $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016, damaging investors.
If you suffered a loss in Endologix you have until March 6, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
